A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
Фаза 1 – тестване на безопасността при малка група хора
Заболявания:
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Спонсор: Bristol-Myers Squibb Services Unlimited Company
Налично на:
БГ
Обобщение
Trial status: Authorised
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 35 participants
БГ
EN